Amgen Inc.

University of Florida Research Foundation, Incorporated

Jerry Ryan Holder

Leslie Phillip Miranda

James Richard Falsey

Bin Wu

Shu-Chen Lu

Shanaka Stanislaus

Christopher Michael Tegley

Anthony B Reed

Michael J Frohn

Yuan Cheng

Brian Alan Lanman

Alexander J Pickrell

Aaron C Siegmund

John Gordon Allen

Lewis D Pennington

Elizabeth M Doherty

Bryant Yang

Gayathri Swaminath

Murielle M Veniant-Ellison

Bradley J Herberich

Carrie Haskell-Luevano

Junming Yie

Justin K Murray

Malgorzata Wanska

Chawita Netirojjanakul

Kenneth William Walker

Jing M Xu

Thomas Nixey

Kelvin C Sham

Kaustav Biswas

Derin C D'amico

Colin Victor Gegg, Jr

David J Lloyd

Jing Xu

Jason C Long

Marie E Wright

Eileen J Johnson

Kelvin Sham

Murielle M Venient-Ellison

Jennifer Aral

Method of treating metabolic diseases and disorders using a composition comprising a GLP-V/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Apelin polypeptides

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Potent and selective inhibitors of Nav1.7

[object Object]

Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.

CGRP peptide antagonists and conjugates

The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula:X-Z-Q-arg-trp-NHwherein: Xis an acyl group, Z is amino-2-naphthyl-carboxylic acid or histidine, Q is (D)phenylalanine or p-iodo-(D)phenylalanine, or a pharmacologically acceptable salt, complex or derivative thereof, the peptide derivative having melanocortin-4 receptor agonist activity.

Peptides and methods for the control of obesity

The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula:X-Z-Q-arg-trp-NH

Growing community of inventors

Simi Valley, CA, United States of America

Jerry Ryan Holder